Year-end Sale % OFF 
Abstract
KEYNOTE-024 compared single agent pembrolizumab to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) with PDL1 >50%, illustrating improved progression free survival (PFS) and overall survival (OS) for pembrolizumab. The objective of this study is to identify the proportion of real-world NSCLC patients who have a long-term benefit with first line pembrolizumab and examine their characteristics compared to patients who show limited benefit to the drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
